JOHNS HOPKINS UNIVERSITY

Analysis of FDA adverse event data reveals dual orexin receptor antagonists (DORAs) have only 2.6% abuse-related adverse events, significantly lower than benzodiazepines (27.7%) and Z-drugs (15.3%).

Rapafusyn Pharmaceuticals closed an over-subscribed $44 million Series A financing round, adding BioTrack Capital and Yonjin Capital as new investors alongside existing backers.

Raina Biosciences announced publication of its GEMORNA platform data in Science, marking the world's first generative AI platform purpose-built for mRNA design and optimization.

Precision BioSciences' PBGENE-HBV demonstrated substantial antiviral activity in all three patients in the lowest dose cohort, achieving 47-69% reductions in hepatitis B surface antigen levels.

A BMJ investigation has revealed evidence of serious misreporting in two clinical trials that were pivotal to ticagrelor's approval by the FDA and UK regulators.

Infinity Bio closed an $8 million Series A financing round led by Illumina Ventures to expand its proprietary MIPSA™ antibody reactome profiling platform.

A peer-reviewed narrative review published in Cureus journal highlights the therapeutic potential of long-acting synthetic cannabidiol (CBD) for chronic pain management as a non-opioid alternative.

The CheckMate 816 phase 3 trial demonstrates that patients with resectable non-small cell lung cancer who received nivolumab plus chemotherapy before surgery had approximately 10% higher survival rates at 5 years compared to chemotherapy alone.

LP-184 showed remarkable survival improvements in mouse models of atypical teratoid rhabdoid tumors (ATRT), with median survival increasing by 345% in one model (p<0.0001).

The Maryland Stem Cell Research Commission has awarded over $18 million in grants to 52 investigators working on nearly 50 different medical conditions including sickle cell anemia, diabetes, and various neurological disorders.